Is GLP-1 coverage actually delivering value?

For the past few years, benefits consultants have spent considerable energy helping employers understand and navigate the dynamic GLP-1 landscape. It's a space moving faster than most can keep up with: new drugs entering the market, new indications and mounting cost pressures. 

Initially, employers grappled with the dilemma of whether to cover GLP-1s. Notably, the conversation has shifted with employers and benefits leaders are now trending in favor of coverage, settling this conundrum.

The new question — and arguably the more difficult one to answer — is whether the employer's investment is actually working to deliver value. And this is where brokers have a real opportunity to educate their clients.

Gap between promise and reality

The current generation of GLP-1 medications represent a genuine breakthrough, with compelling clinical trial data ranging from 10% to 20% weight loss across the category. In practice, however, many GLP-1s only deliver single-digit weight loss at 12 months. This gap between what medication can achieve in controlled trials vs. what it actually delivers in a real-world setting is not a pharmaceutical or personal failure. It is a support failure.

A lack of support compromises medication persistence and lifestyle factors remain unaddressed. Members start medications without understanding how to optimize their response through behavioral coaching. They experience side effects without clinical guidance. They lose weight, then plateau and stop the medication and the weight returns – eroding outcomes in the process. Employee health continues to suffer and there's a significant financial concern for employers: a large spend has occurred yet without the promise of lasting results.

The importance of lifestyle change alongside GLP-1 therapy is not a new idea. The landmark trials that established GLP-1 efficacy included lifestyle support as part of the protocol. The World Health Organization's guideline similarly endorses comprehensive behavioral and lifestyle management as part of obesity care. And when you look at data on the habits of individuals who have sustained a loss of at least 30 pounds in the National Weight Control Registry, significant lifestyle changes have been made to maintain the lost weight. It also bears mention that this doesn't just apply to the disease of obesity; for many chronic metabolic diseases such as type 2 diabetes, hyperlipidemia and hypertension, improving nutrition and activity leads to better outcomes. 

When structured behavioral support addresses diet, exercise, sleep and emotional stressors that can drive abnormal weight gain, it amplifies medication efficacy, improves adherence and enhances weight loss. Yet when that support is stripped away, real-world outcomes fall short.

Outcomes data from companies that integrate clinical weight management with coaching offer a useful window into what happens when a structured support program is in place. Members on GLP-1s integrated with coaching experience as high as 16% weight loss in the first 12 months, far outperforming real-world averages, with sustained weight loss observed for over four years. 

Results tend to be consistent across industry type, age and gender and have been shown to be strongest in the highest-risk populations employers worry about most. 

Not all GLP-1 support programs are created equal. From what I've observed in the real world, there is a consistent set of features that distinguish effective support from token add-ons. They include the following: 

• Effective programs are personalized, recognizing that each member brings a different clinical history, set of motivations and pattern of daily life to treatment. 
• They are flexible, designed to meet members where they are even when life gets in the way rather than requiring rigid protocol adherence. 
• They build accountability through consistent human touchpoints, not just app notifications. 
• They integrate clinical oversight and habit-change coaching rather than being delivered as siloed, disconnected services. 

Key questions to ponder

Many employers are focused on formulary design, cost-sharing and prior authorization –all legitimate concerns. But downstream there is a more fundamental question: What does "success" look like for this benefit and how do we get there?

Employers that will get the best return from their GLP-1 investment must treat it as a comprehensive clinical program rather than a prescription benefit. When evaluating a program's features, it's critical to ask the following:

• What support exists for members once they are prescribed a GLP-1? How is the support personalized?
• How do we decide which members will be covered? (Does the program prioritize those with the highest clinical need? How will that be determined beyond just BMI?)
• What is the plan for members who have suboptimal responses, experience plateaus or discontinue medication?
• How are we measuring long-term outcomes beyond weight loss? 
• If there's a gap in outcomes, what's driving it?

These are all questions of clinical governance. Employers embarking on a costly, long-term GLP-1 relationship deserve this framework for accountability. 

From coverage to value

Brokers have both an opportunity and responsibility to educate their clients toward better health outcomes and less financial volatility, not just a yes/no on coverage.

And it's pretty obvious that cost and value are not the same thing. A $15,000 annual GLP-1 spend that delivers single-digit weight loss, no meaningful metabolic improvements and a high discontinuation rate is not a solid investment. The same spend paired with structured clinical and lifestyle support that delivers 17% to 20% sustained weight loss, meaningful reductions in metabolic risk and measurable downstream healthcare savings is a fundamentally different calculation. 

The shift in thinking from "should we cover GLP-1s" to "how do we ensure we're getting value from this spend" is already underway among forward-thinking employers. Benefits consultants can accelerate that shift, and in doing so, provide the kind of guidance that advances population health while keeping runaway employer costs in check.